(BAX) Baxter International - Ratings and Ratios
IV Fluids, IV Systems, Injectable Drugs, Surgical Products, Hospital Beds
BAX EPS (Earnings per Share)
BAX Revenue
Description: BAX Baxter International
Baxter International Inc. is a healthcare company with a diverse portfolio of medical products and therapies. The company operates through three main segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals, catering to various healthcare settings, including hospitals, nursing homes, and patients at home.
The companys product offerings include sterile IV solutions, infusion systems, parenteral nutrition therapies, surgical equipment, patient monitoring technologies, and respiratory health devices. Baxter also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its global presence spans across multiple regions, including Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand.
From a financial perspective, Baxters market capitalization stands at approximately $14.7 billion. The companys forward Price-to-Earnings ratio is 11.39, indicating a relatively reasonable valuation. However, the Return on Equity (RoE) is -7.58%, suggesting that the company has faced challenges in generating profits for its shareholders. To further analyze the companys performance, key metrics such as Revenue Growth, Operating Margin, and Debt-to-Equity ratio can be examined. For instance, a review of Baxters revenue growth over the past few years can help assess its ability to expand its business. Additionally, analyzing the companys operating margin can provide insights into its pricing power and cost management. A Debt-to-Equity ratio analysis can also help evaluate Baxters capital structure and potential financial risks.
To gain a deeper understanding of Baxters stock performance, its dividend yield, beta, and trading volume can be analyzed. For example, a review of the companys dividend yield can help income-focused investors assess its attractiveness. Moreover, analyzing Baxters beta can provide insights into its stock price volatility relative to the broader market. Trading volume analysis can also help investors gauge the liquidity of the stock and potential trading costs.
BAX Stock Overview
| Market Cap in USD | 12,579m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1981-10-27 |
BAX Stock Ratings
| Growth Rating | -84.4% |
| Fundamental | 34.5% |
| Dividend Rating | 22.2% |
| Return 12m vs S&P 500 | -49.1% |
| Analyst Rating | 3.44 of 5 |
BAX Dividends
| Dividend Yield 12m | 2.51% |
| Yield on Cost 5y | 0.92% |
| Annual Growth 5y | 1.40% |
| Payout Consistency | 40.5% |
| Payout Ratio | 30.8% |
BAX Growth Ratios
| Growth Correlation 3m | -75.3% |
| Growth Correlation 12m | -75.9% |
| Growth Correlation 5y | -92.2% |
| CAGR 5y | -24.06% |
| CAGR/Max DD 3y | -0.40 |
| CAGR/Mean DD 3y | -0.73 |
| Sharpe Ratio 12m | -0.91 |
| Alpha | -48.32 |
| Beta | 0.370 |
| Volatility | 33.82% |
| Current Volume | 7038k |
| Average Volume 20d | 5749.9k |
| Stop Loss | 23 (-3.4%) |
| Signal | -0.07 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-155.0m TTM) > 0 and > 6% of Revenue (6% = 653.2m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.00% (prev 19.26%; Δ 15.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 765.0m > Net Income -155.0m (YES >=105%, WARN >=100%) |
| Net Debt (8.04b) to EBITDA (910.0m) ratio: 8.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (514.0m) change vs 12m ago 0.78% (target <= -2.0% for YES) |
| Gross Margin 36.59% (prev 38.48%; Δ -1.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.98% (prev 48.59%; Δ -2.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.09 (EBITDA TTM 910.0m / Interest Expense TTM 354.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.42
| (A) 0.18 = (Total Current Assets 6.75b - Total Current Liabilities 2.94b) / Total Assets 21.05b |
| (B) 0.71 = Retained Earnings (Balance) 14.97b / Total Assets 21.05b |
| (C) 0.00 = EBIT TTM 32.0m / Avg Total Assets 23.68b |
| (D) 0.87 = Book Value of Equity 11.91b / Total Liabilities 13.75b |
| Total Rating: 4.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.49
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 1.63% = 0.82 |
| 3. FCF Margin 3.06% = 0.76 |
| 4. Debt/Equity 1.30 = 1.71 |
| 5. Debt/Ebitda 10.44 = -2.50 |
| 6. ROIC - WACC -4.35% = -5.43 |
| 7. RoE -2.12% = -0.35 |
| 8. Rev. Trend -61.67% = -4.63 |
| 9. EPS Trend -57.87% = -2.89 |
What is the price of BAX shares?
Over the past week, the price has changed by -1.20%, over one month by -0.88%, over three months by -22.24% and over the past year by -39.54%.
Is Baxter International a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAX is around 17.54 USD . This means that BAX is currently overvalued and has a potential downside of -26.3%.
Is BAX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29 | 21.8% |
| Analysts Target Price | 29 | 21.8% |
| ValueRay Target Price | 18.9 | -20.8% |
Last update: 2025-09-13 04:31
BAX Fundamental Data Overview
CCE Cash And Equivalents = 1.69b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.7943
P/S = 1.1554
P/B = 1.7184
P/EG = 1.9974
Beta = 0.604
Revenue TTM = 10.89b USD
EBIT TTM = 32.0m USD
EBITDA TTM = 910.0m USD
Long Term Debt = 9.49b USD (from longTermDebt, last quarter)
Short Term Debt = 8.00m USD (from shortTermDebt, last quarter)
Debt = 9.50b USD (Calculated: Short Term 8.00m + Long Term 9.49b)
Net Debt = 8.04b USD (from netDebt column, last quarter)
Enterprise Value = 20.39b USD (12.58b + Debt 9.50b - CCE 1.69b)
Interest Coverage Ratio = 0.09 (Ebit TTM 32.0m / Interest Expense TTM 354.0m)
FCF Yield = 1.63% (FCF TTM 333.0m / Enterprise Value 20.39b)
FCF Margin = 3.06% (FCF TTM 333.0m / Revenue TTM 10.89b)
Net Margin = -1.42% (Net Income TTM -155.0m / Revenue TTM 10.89b)
Gross Margin = 36.59% ((Revenue TTM 10.89b - Cost of Revenue TTM 6.90b) / Revenue TTM)
Tobins Q-Ratio = 1.71 (Enterprise Value 20.39b / Book Value Of Equity 11.91b)
Interest Expense / Debt = 0.76% (Interest Expense 72.0m / Debt 9.50b)
Taxrate = 8.27% (11.0m / 133.0m)
NOPAT = 29.4m (EBIT 32.0m * (1 - 8.27%))
Current Ratio = 2.30 (Total Current Assets 6.75b / Total Current Liabilities 2.94b)
Debt / Equity = 1.30 (Debt 9.50b / last Quarter total Stockholder Equity 7.32b)
Debt / EBITDA = 10.44 (Net Debt 8.04b / EBITDA 910.0m)
Debt / FCF = 28.53 (Debt 9.50b / FCF TTM 333.0m)
Total Stockholder Equity = 7.31b (last 4 quarters mean)
RoA = -0.74% (Net Income -155.0m, Total Assets 21.05b )
RoE = -2.12% (Net Income TTM -155.0m / Total Stockholder Equity 7.31b)
RoCE = 0.19% (Ebit 32.0m / (Equity 7.31b + L.T.Debt 9.49b))
RoIC = 0.16% (NOPAT 29.4m / Invested Capital 18.72b)
WACC = 4.50% (E(12.58b)/V(22.08b) * Re(7.38%)) + (D(9.50b)/V(22.08b) * Rd(0.76%) * (1-Tc(0.08)))
Shares Correlation 3-Years: 82.24 | Cagr: 0.18%
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈404.2m ; Y1≈265.4m ; Y5≈121.4m
Fair Price DCF = 4.64 (DCF Value 2.39b / Shares Outstanding 513.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -57.87 | EPS CAGR: -11.28% | SUE: -0.17 | # QB: False
Revenue Correlation: -61.67 | Revenue CAGR: -8.70%
Additional Sources for BAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle